-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Aglatimagene Besadenovec in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Aglatimagene Besadenovec in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Aglatimagene Besadenovec in Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewRecurrent Malignant Glioma – Drugs In Development, 2024
Empower your strategies with our Recurrent Malignant Glioma  – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent malignant glioma is defined as the recurrence of a glioma tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back,...
-
Product Insights
NewEpendymoma – Drugs In Development, 2024
Empower your strategies with our Ependymoma – Drugs In Development, 2024 report and make more profitable business decisions. Ependymoma is a type of glioma that develops from ependymal cells. Ependymomas usually develop in the lining of the ventricles or in the spinal cord. The most common place they are found in children is near the cerebellum. The tumor often blocks the flow of cerebral spinal fluid (CSF), causing increased intracranial pressure. Ependymomas are often slow-growing tumours, and any signs and symptoms...
-
Product Insights
NewAnaplastic Astrocytoma – Drugs In Development, 2024
Empower your strategies with our Anaplastic Astrocytoma – Drugs In Development, 2024 report and make more profitable business decisions. Anaplastic astrocytoma is a grade III tumor that accounts for 2% of all brain tumors. It is a type of glioma that develops from star-shaped glial cells (astrocytes), which support nerve cells. Anaplastic astrocytoma grows faster and more aggressively than grade II astrocytomas. The tumor cells are not uniform in appearance and invade neighboring tissue. Symptoms include headache, weakness, clumsiness, difficulty walking,...
-
Product Insights
NewChemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2024
Empower your strategies with our Chemotherapy Induced Peripheral Neuropathy – Drugs In Development, 2024 report and make more profitable business decisions. Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes, and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy, and type of chemotherapeutic agent. The Chemotherapy Induced Peripheral Neuropathy drugs in development market research report provide comprehensive information on the therapeutics under development for Chemotherapy...
-
Product Insights
NewMalignant Glioma – Drugs In Development, 2024
Empower your strategies with our Malignant Glioma – Drugs In Development, 2024 report and make more profitable business decisions. Malignant gliomas are aggressive and fast-growing tumors that arise from glial cells in the brain and spinal cord. Gliomas account for the most common type of primary brain tumors in adults. Symptoms of malignant gliomas vary depending on the tumor's size, location, and rate of growth. Common symptoms may include headaches, seizures, cognitive changes, personality or behavior changes, weakness or sensory loss,...
-
Product Insights
NewHigh-Grade Glioma – Drugs In Development, 2024
Empower your strategies with our High-Grade Glioma – Drugs In Development, 2024 report and make more profitable business decisions. High-grade gliomas (HGGs) are tumors of the central nervous system that arise from mutated cells of the brain and spinal cord. Symptoms include developmental delay, headaches, backaches, nausea and vomiting, dizziness, gait disturbances, impaired vision, lack of concentration, drowsiness, sleep disturbances, dysregulated appetite, paralysis, and seizures. Treatment includes chemotherapy and radiation therapy. The High-Grade Glioma drugs in development market research report provide...
-
Product Insights
NewRecurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024
Empower your strategies with our Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2024 report and make more profitable business decisions. Recurrent glioblastoma multiforme (GBM) refers to the return of aggressive brain tumors known as glioblastomas after initial treatment. GBM is the most malignant type of glioma, characterized by rapid growth and infiltrative behavior. Despite aggressive therapies like surgery, radiation, and chemotherapy, GBM often recurs due to its invasive nature and resistance to treatment. Management of recurrent GBM poses significant challenges....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BIA-286156 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BIA-286156 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BIA-286156 in Parkinson's Disease Drug Details: BIA-286156 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Eftozanermin Alfa in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftozanermin Alfa in Solid Tumor report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Eftozanermin Alfa in Solid Tumor Drug Details:Eftozanermin alfa (ABBV-621) is under development...